A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

September 9, 2020

Study Completion Date

January 27, 2021

Conditions
Endometrial CancerUterine CancerOvarian CancerCarcinosarcoma
Interventions
DRUG

Paclitaxel

Administered by IV infusion

DRUG

300mg DKN-01

Administered by IV infusion

DRUG

600mg DKN-01

Administered by IV infusion

Trial Locations (17)

22903

University of Virginia Cancer Center, Charlottesville

33401

Florida Cancer Specialists & Research Institute, West Palm Beach

35294

University of Alabama, Birmingham

37203

Tennessee Oncology, PLLC, Nashville

37232

Vanderbilt University Medical Center, Nashville

38138

The University of Tennessee West Cancer Center, Germantown

43026

Ohio State University Wexner Medical Center, Hilliard

44195

Cleveland Clinic, Cleveland

53226

Froedtert and Medical College of Wisconsin, Milwaukee

53715

University of Wisconsin, Madison

60637

University of Chicago, Chicago

64132

HCA Midwest Health System Clinical Research, Kansas City

73104

Stephenson Cancer Center - University of Oklahoma Health Sciences Center, Oklahoma City

75390

University of Texas Southwestern Medical Center, Dallas

85258

HonorHealth, Scottsdale

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Leap Therapeutics, Inc.

INDUSTRY

NCT03395080 - A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | Biotech Hunter | Biotech Hunter